Home
Science & Technology
Publications

Publications:
Our Research

Filter

Filter

Research Area
Technology
Resource type
Category
216 results found
Oct 16, 2024
Publication
Novavax led
JMIR public health and surveillance
COVID-19 Vaccine Preferences in General Populations in Canada, Germany, the United Kingdom, and the United States: Discrete Choice Experiment
David Salisbury, Jeffrey V Lazarus, Nancy Waite, et al.
View
Oct 15, 2024
Publication
Collaborative
Journal of Infection
COVID-19, Matrix-M® adjuvant
Mechanisms and Implications of IgG4 Responses to SARS-CoV-2 and Other Repeatedly Administered Vaccines
Marchese AM, Fries L, Beyhaghi H, et al.
View
Oct 11, 2024
Pre-print
Novavax led
Seasonal influenza, Matrix-M® adjuvant
A Modified Novel Validated High-Throughput Hemagglutinin Inhibition Assay Using Recombinant Virus-Like Particles and Human Red Blood Cells for the Objective Evaluation of Recombinant Hemagglutinin Nanoparticle Seasonal Influenza Vaccine
Timothy S. Vincent, Mingzhu Zhu, Anand Parekh, et al.
View
Sep 27, 2024
Publication
Novavax led
Journal of Infection
COVID-19, Matrix-M® adjuvant
Immunogenicity and Safety of SARS-CoV-2 Recombinant Spike Protein Vaccine in South African People Living With and Without HIV-1 Infection: A Phase 2 Randomised Trial
Chijioke Bennett, Zaheer Hoosain, Anthonet Koen, et al.
View
Sep 26, 2024
Publication
Novavax included/third party
Clinical Infectious Diseases
COVID-19, Matrix-M® adjuvant
Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial
Fong Y, Dang L, Zhang B, et al.
View
Sep 3, 2024
Publication
Collaborative
The Journal of Infectious Diseases
COVID-19, Matrix-M® adjuvant
Association Between SARS-CoV-2 Viral Load and COVID-19 Vaccination in 4 Phase 3 Trials
Janes H, Fisher LH, Kee JJ, et al.
View
Aug 15, 2024
Publication
Collaborative
Clinical Infectious Diseases
COVID-19, Matrix-M® adjuvant
COVID-19 Vaccine Efficacy in Participants with Weakened Immune Systems From 4 Randomized Controlled Trials
Sherman AC, Tuan J, Cantos VD, et al.
View
Aug 15, 2024
Publication
Collaborative
Clinical Infectious Diseases
COVID-19, Matrix-M® adjuvant
COVID-19 vaccine efficacy in participants with weakened immune systems from four randomized-controlled trials
Sherman A, Tuan J, Cantos VD, et al.
View
Jul 19, 2024
Publication
Novavax led
Vaccines
COVID-19, Matrix-M® adjuvant
Reactogenicity Differences between Adjuvanted, Protein-Based and Messenger Ribonucleic Acid (mRNA)-Based COVID-19 Vaccines
Matthew D. Rousculp, Kelly Hollis, Ryan Ziemiecki, et al.
View
Jul 14, 2024
Publication
Novavax led
microorganisms
COVID-19, Matrix-M® adjuvant
Validation of a Pseudovirus Neutralization Assay for Severe Acute Respiratory Syndrome Coronavirus 2: A High-Throughput Method for the Evaluation of Vaccine Immunogenicity
Raj Kalkeri, Ph.D., Mingzhu Zhu, Ph.D., Shane Cloney-Clark B.Sc, et al.
View